Small Cell Lung Cancer Guideline Updates 2020 | articles

Before the approval of lurbinectedin, just 1 drug—topotecan—had approval for this indication, leaving these patients with few treatment options after progressing on their initial therapy.

In June, lurbinectedin became just the second approved treatment for patients whose metastatic small cell lung cancer (SCLC) has progressed on or after platinum-based chemotherapy, joining topotecan.